Expanded EU Approval For Roche's Perjeta In Early Stage Breast Cancer
This article was originally published in Scrip
The European Commission (EC) has approved Roche Holding AG's Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy, for use before surgery in adult patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.